These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37252140)

  • 41. Dose-dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophrenia.
    Suzuki Y; Ono S; Sugai T; Fukui N; Watanabe J; Tsuneyama N; Sawamura K; Someya T
    Hum Psychopharmacol; 2011 Aug; 26(6):440-3. PubMed ID: 21823168
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia.
    Lu ML; Wu YX; Chen CH; Kuo PT; Chen YH; Lin CH; Wu TH
    PLoS One; 2016; 11(2):e0148539. PubMed ID: 26849777
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.
    Narula PK; Rehan HS; Unni KE; Gupta N
    Schizophr Res; 2010 May; 118(1-3):218-23. PubMed ID: 20207521
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Simvastatin improves olanzapine-induced dyslipidemia in rats through inhibiting hepatic mTOR signaling pathway.
    Liu XM; Zhao XM; Deng C; Zeng YP; Hu CH
    Acta Pharmacol Sin; 2019 Aug; 40(8):1049-1057. PubMed ID: 30728467
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.
    Crawford AM; Beasley CM; Tollefson GD
    Schizophr Res; 1997 Jul; 26(1):41-54. PubMed ID: 9376336
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Increased growth hormone secretagogue receptor-1a (GHSR-1a) in hypothalamus during olanzapine treatment in rats.
    Tunçel ÖK; Altunkaynak Z; Bilgici B; Karaustaoğlu A; Gümrükçüoğlu Tİ
    Psychoneuroendocrinology; 2022 Oct; 144():105862. PubMed ID: 35835020
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A randomized-controlled trial of blonanserin and olanzapine as adjunct to antipsychotics in the treatment of patients with schizophrenia and dopamine supersensitivity psychosis: The ROADS study.
    Niitsu T; Hata T; Nishimoto M; Hosoda Y; Kimura A; Oda Y; Suzuki M; Takase N; Seki R; Fujita K; Endo M; Yoshida T; Inoue M; Hattori N; Murakami T; Imamura Y; Ogawa K; Fukami G; Sato T; Kawasaki Y; Hashimoto T; Ishikawa M; Shiina A; Kanahara N; Iyo M;
    Asian J Psychiatr; 2020 Oct; 53():102369. PubMed ID: 32920492
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Determination of olanzapine and N-desmethyl-olanzapine in plasma using a reversed-phase HPLC coupled with coulochemical detection: correlation of olanzapine or N-desmethyl-olanzapine concentration with metabolic parameters.
    Lu ML; Lin CH; Chen YC; Yang HC; Wu TH
    PLoS One; 2013; 8(5):e65719. PubMed ID: 23741510
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine.
    Yamashita H; Yoda H; Kuroki N; Kuwabara M; Odagaki Y; Kazawa T; Toyoshima R; Maruki T
    Psychopharmacology (Berl); 2011 Jan; 213(1):1-9. PubMed ID: 20820759
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Amantadine for weight gain associated with olanzapine treatment.
    Deberdt W; Winokur A; Cavazzoni PA; Trzaskoma QN; Carlson CD; Bymaster FP; Wiener K; Floris M; Breier A
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):13-21. PubMed ID: 15572269
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Olanzapine Plus Samidorphan in Subjects with Schizophrenia and Comorbid Alcohol Use Disorder: Rationale and Design for a Phase II, Double-blind, Randomized Study.
    Citrome L; O'Malley SS; McDonnell D; Jiang Y; Simmons AC; Berry MP; Dipetrillo LE
    Innov Clin Neurosci; 2019 May; 16(5-6):15-21. PubMed ID: 31440397
    [No Abstract]   [Full Text] [Related]  

  • 52. Probiotics Plus Dietary Fiber Supplements Attenuate Olanzapine-Induced Weight Gain in Drug-Naïve First-Episode Schizophrenia Patients: Two Randomized Clinical Trials.
    Huang J; Kang D; Zhang F; Yang Y; Liu C; Xiao J; Long Y; Lang B; Peng X; Wang W; Wang X; Liu F; Davis JM; Zhao J; Wu R
    Schizophr Bull; 2022 Jun; 48(4):850-859. PubMed ID: 35569003
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preliminary Examination of Olanzapine and Diet Interactions On Metabolism in a Female Macaque.
    Varlamov O; Kievit P; Phu K; Reddy AP; Roberts CT; Bethea CL
    J Endocrinol Diabetes; 2014; 1(2):. PubMed ID: 25621305
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial.
    Kennedy JS; Jeste D; Kaiser CJ; Golshan S; Maguire GA; Tollefson G; Sanger T; Bymaster FP; Kinon BJ; Dossenbach M; Gilmore JA; Breier A
    Int J Geriatr Psychiatry; 2003 Nov; 18(11):1013-20. PubMed ID: 14618553
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities.
    Cooper GD; Pickavance LC; Wilding JP; Harrold JA; Halford JC; Goudie AJ
    J Psychopharmacol; 2007 Jun; 21(4):405-13. PubMed ID: 17050655
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metformin Attenuates Liver Fat Content: Finding from Schizophrenia Patients with Olanzapine-induced Weight Gain.
    Wang L; Chen Y; Sui YC; Tan XQ; Zhou Z; Li N; Xu LP
    Clin Psychopharmacol Neurosci; 2020 Feb; 18(1):67-74. PubMed ID: 31958907
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of olanzapine on resting heart rate in Japanese patients with schizophrenia.
    Tajiri M; Suzuki Y; Sugai T; Tsuneyama N; Someya T
    PLoS One; 2018; 13(7):e0199922. PubMed ID: 30016331
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Samidorphan/olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials.
    Rehan ST; Siddiqui AH; Khan Z; Imran L; Syed AA; Tahir MJ; Jassani Z; Singh M; Asghar MS; Ahmed A
    Ann Med Surg (Lond); 2022 Jul; 79():104115. PubMed ID: 35860157
    [TBL] [Abstract][Full Text] [Related]  

  • 59. "Long-acting" olanzapine in maintenance therapy of schizophrenia: A study with plasma levels.
    Mauri MC; Maffini M; Di Pace C; Reggiori A; Paletta S; Moliterno D; Rovera C; Altamura CA
    Int J Psychiatry Clin Pract; 2015 Jun; 19(2):99-105. PubMed ID: 25547438
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The protective effect of olanzapine on ketamine induced cognitive deficit and increased NR1 expression in rat model of schizophrenia.
    Mahmoud GS; Hosny G; Sayed SA
    Int J Physiol Pathophysiol Pharmacol; 2021; 13(2):22-35. PubMed ID: 34093963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.